Kura Oncology, Inc. (NASDAQ:KURA) Insider Mollie Leoni Sells 4,963 Shares

Kura Oncology, Inc. (NASDAQ:KURA) insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Kura Oncology Price Performance

Kura Oncology stock opened at $7.69 on Thursday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $9.06 and its 200 day simple moving average is $15.63. Kura Oncology, Inc. has a 52 week low of $6.98 and a 52 week high of $24.17. The firm has a market capitalization of $598.01 million, a PE ratio of -3.26 and a beta of 0.81.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same quarter last year, the business earned ($0.50) earnings per share. On average, equities research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Analyst Ratings Changes

KURA has been the topic of a number of analyst reports. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $26.00 to $19.00 in a report on Monday, October 14th. Jefferies Financial Group cut their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Scotiabank decreased their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Finally, TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently made changes to their positions in KURA. Hsbc Holdings PLC increased its position in Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after purchasing an additional 2,167 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Kura Oncology during the second quarter worth about $541,000. AQR Capital Management LLC raised its position in shares of Kura Oncology by 251.5% in the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after buying an additional 58,422 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares during the period. Finally, Quarry LP acquired a new stake in Kura Oncology during the second quarter worth approximately $196,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.